32 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28231433	101	Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits.	Pfizer
27255176	111	Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.	Peking Union Medical College and Chinese Academy of Medical Sciences
26985306	18	Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.	Virginia Tech
27190598	26	Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.	University of Virginia
26780304	22	From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).	Monash University (Parkville Campus)
25862200	4	Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.	Virginia Tech
25643074	26	Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.	Virginia Tech
25150091	2	Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors.	Goethe University
24471412	12	Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.	Penn State Hershey Cancer Institute
24164513	9	Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors.	The City University of New York
23845219	142	Structure guided design of a series of sphingosine kinase (SphK) inhibitors.	Amgen
23360348	11	Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Ka.	Celgene Avilomics Research
22321213	16	Effect of alkyl chain length on sphingosine kinase 2 selectivity.	Virginia Tech
22137932	17	Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.	Virginia Tech
21495716	59	Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.	University of Virginia
19467599	16	Iodophenyl tagged sphingosine derivatives: synthesis and preliminary biological evaluation.	University of Pennsylvania
19469544	7	Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases.	National University of Singapore
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
27429068	54	Evolution of a Novel, Orally Bioavailable Series of PI3K? Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.	Glaxosmithkline R&D
30889352	39	Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2.	Heriot-Watt University
31895563	29	Discovery of a Small Side Cavity in Sphingosine Kinase 2 that Enhances Inhibitor Potency and Selectivity.	Virginia Tech
24396570	9	Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.	The City University of New York
29969256	21	Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.	Universitaire Vaudois
28406646	24	Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.	University of Virginia
28408190	60	Identification of selective inhibitors of sphingosine kinases 1 and 2 through a structure-activity relationship study of 4-epi-jaspine B.	Kyoto University
28347666	45	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3K?/? inhibitors for the treatment of PTEN-deficient tumours.	Astrazeneca
17466326	4	Crystal structures of multidrug binding protein TtgR in complex with antibiotics and plant antimicrobials.	Imperial College